CD 6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission

The appropriate timing of bone marrow transplantation cells from donor marrow. No preor posttransplant immune (BMT) for adults with acute myelogenous leukemia (AML) suppressive medications for GVHD prophylaxis were adminand acute lymphoblastic leukemia (ALL) is controversial. Alistered. The actuarial estimated risk of grade 2 to 4 acute though allogeneic transplantation results in a lower risk of GVHD was 15% in patients receiving HLA identical grafts. disease recurrence than intensive chemotherapy alone, Chronic GVHD developed in five patients. The estimated risk overall outcome following BMT may not be improved due to of TRM for patients in first complete remission was 5% at the higher incidence of therapy-related fatal complications, Day "100 and 16% at 2 years. Fatalities attributable to infecfrequently as a result of the development of graft-versustion with cytomegalovirus or Epstein-Barr virus occurred in host disease (GVHD). Selective T-cell depletion of donor only three patients. Estimated probabilities of relapse, overmarrow can reduce the incidence of GVHD and thereby limit all survival, and event-free survival at 4 years were 25%, transplant-related toxicity. Herein we report the risk of 71%, and 63%, respectively. No significant differences in GVHD, incidence of transplant related mortality (TRM), likeliGVHD, TRM, relapse rate, or survival was observed for pahood of disease relapse, and overall survival in adult patients tients with AML compared with those with ALL. Allogeneic undergoing BMT with CD6 depleted allogeneic marrow for transplantation with CD6 depleted bone marrow is effective acute leukemia in first remission. Forty-one consecutive alloin consolidating remissions of high-risk patients with acute geneic transplants were performed on patients with acute leukemia in first remission without excessive toxicity. leukemia and high-risk features (28 AML, 13 ALL) using T12 q 1997 by The American Society of Hematology. monoclonal antibody and complement to remove CD6" T